MAPT and Alzheimer disease: One strategy to address alcohol’s impact on AD-like symptoms is to assay the effects of alcohol in transgenic mouse models of AD that develop cognitive decline with aging, in concert with the manifestation of biomarkers of AD (e.g., accumulation of phosphorylated tau, Aβ1–40, Aβ1–42, neuritic plaque formation, etc.; e.g., Webster et al., 2014; Hu et al., 2015; Jankowsky and Zheng, 2017).